Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [3] - The company aims to create therapies that precisely target cancer cells while sparing healthy cells, enhancing specificity, and controlling drug expression post-administration [3] - Senti Bio's pipeline includes off-the-shelf CAR-NK cells equipped with Gene Circuits for targeting difficult liquid and solid tumors, and it has shown preclinical success in T cells and other modalities [3] Recent Developments - On November 26, 2024, Senti Bio's Compensation Committee granted stock options to three new employees, totaling 49,778 shares at an exercise price of $2.11 per share [1] - These stock options were awarded as an inducement for the employees to join the company, in compliance with NASDAQ Listing Rule 5635(c)(4) [2] - The stock options were granted under the Company's 2022 Inducement Equity Plan, which was adopted on August 5, 2022 [2]

Core Insights - Senti Biosciences, Inc. announced positive initial data from a phase I study for its CAR-NK cell therapy candidate, SENTI-202, targeting relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [1][4][7] Company Performance - Following the announcement, Senti Biosciences' shares surged by 363% on December 2 [2] - Year-to-date, SNTI stock has increased by 51.5%, contrasting with a 7.1% decline in the industry [3] Clinical Study Results - In the phase I study, two out of three AML patients treated at the lowest dose level (1.0 billion CAR+ NK cells) achieved complete remission, confirmed by bone marrow biopsy [4] - Both patients also achieved measurable residual disease (MRD) negative status, indicating no detectable cancer cells [5] - Treatment with SENTI-202 was generally well-tolerated among all three AML patients [6] Future Developments - The FDA cleared Senti Biosciences' IND application for SENTI-202 in December 2022, allowing clinical studies to commence [7] - The phase I study is expected to enroll around 20 patients, with a higher dose cohort currently enrolling [8] - Additional safety and efficacy data, including durability data, is anticipated in 2025 [9] Pipeline Expansion - Senti Biosciences has another candidate, SENTI-301A, and has entered a collaboration with Celest Therapeutics for its clinical development in China [10]

Senti Biosciences, Inc. SNTI stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro.The company reported initial clinical data from a Phase 1 trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, for relapsed/refractory hematologic malignancies including acute myeloid leukemia.SENTI-202 is designed to selectiv ...

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the third quarter of 2024 and provided a summary of recent pipeline and corporate highlights. “Over the past quarter, we have continued to execute on our clinical milestones and look forward to sharing initial results fro ...

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, including SENTI-202, a Logic Gated off-the-shelf CARNK investigational cell therapy in Phase 1 clinical trials, today announced its participation at the following investor conferences: H.C. Wainwright's 26th Annual Global Investment Conference Format: Prese ...

Financial Performance - Senti Bio reported a net loss of $11.2 million for Q2 2024, compared to $18.7 million in the same period in 2023[4][10] - Cash and cash equivalents stood at $15.9 million as of June 30, 2024, down from $35.9 million at the end of 2023[4][9] - Total assets decreased to $86.9 million as of June 30, 2024, from $119.5 million at the end of 2023[9] Research and Development (R&D) - R&D expenses increased to $9.2 million in Q2 2024, up from $6.9 million in Q2 2023, primarily due to manufacturing costs for wholly-owned programs[4][10] - Senti Bio received an $8 million grant from CIRM to support the clinical development of SENTI-202 for relapsed/refractory hematologic malignancies[2] - Patient dosing has commenced in the Phase 1 clinical trial of SENTI-202 for AML, with initial efficacy data expected by year-end 2024[3] - Senti Bio plans to initiate a pilot trial of SENTI-301A for hepatocellular carcinoma in China through a partnership with Celest, with first patient dosing expected in Q4 2024[3] General and Administrative (G&A) Expenses - G&A expenses decreased to $4.2 million in Q2 2024, down from $9.2 million in Q2 2023, mainly due to a reduction in headcount[4][10] Corporate Actions - The company effected a 1-for-10 reverse stock split in July 2024 to comply with Nasdaq's minimum bid price requirement[3] Receivables and Transactions - Senti Bio anticipates $18.9 million in receivables from the GeneFab transaction upon satisfaction of certain conditions[4]

– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM for the clinical development of SENTI-202 – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported fina ...

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines ("CIRM"). Pursuant to the executed agreement with CIRM, the first tranche of the grant award is expected to be received in August 2024. The CIRM grant wil ...

Core Insights - Senti Biosciences, Inc. has received an $8 million grant from the California Institute for Regenerative Medicines to support the clinical development of its investigational cell therapy SENTI-202 for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia [1][2] Company Overview - Senti Bio is a biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, aiming to create therapies with enhanced precision and control [6] - The company is advancing its pipeline with off-the-shelf CAR-NK cells designed to target challenging liquid and solid tumor indications [6] Product Development - SENTI-202 is a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies while sparing healthy bone marrow cells [3] - The therapy includes three main components: an OR GATE for activating CAR targeting, a NOT GATE for protecting healthy cells, and calibrated-release IL-15 technology to enhance cell persistence and activity [3] - A Phase 1 clinical trial for SENTI-202 is currently enrolling adult patients with relapsed/refractory CD33 and/or FLT3 expressing hematologic malignancies, with initial efficacy data expected by the end of 2024 [2][3] Market Context - Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults, with an estimated 20,800 new cases in the U.S. in 2024 and a five-year survival rate of approximately 30% [5] - Current treatment options for relapsed or refractory AML are limited, with median overall survival typically less than seven months [5]

Forward-Looking Statements This press release contains certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended including statements with respect to Senti Bio's ability to regain compliance with Nasdaq's continued listing standards and remain listed on Nasdaq or any other major stock exchange and other statements that are forwar ...